Literature DB >> 18054013

Transarterial embolisation for intractable post-traumatic oronasal haemorrhage following traumatic brain injury: evaluation of prognostic factors.

Cheng-Chih Liao1, Yuan-Yun Tseng, Chien-Tzung Chen.   

Abstract

AIM: To analyse the outcomes of transarterial embolisation (TAE) for post-traumatic oronasal haemorrhage following traumatic brain injury (TBI), for clinical application and prognosis.
METHOD: Retrospective review of records of 17 patients treated in the neurosurgical intensive care unit for TBI complicated with intractable post-traumatic oronasal haemorrhage requiring TAE. The Mann-Whitney U-test, Wilcoxon signed rank test and Fisher's exact test were used in statistical analysis.
RESULTS: TAE successfully stopped the post-traumatic oronasal haemorrhage in 13 of 17 cases. The internal maxillary artery was the most common haemorrhaging vessel requiring embolisation. Successful haemostasis contributed significantly to survival.
CONCLUSION: Transarterial embolisation may stop intractable post-traumatic oronasal haemorrhage when conventional packing fails. Shock index (calculated as heart rate/systolic blood pressure) before and after TAE <1.2 and <0.8, respectively, and higher Glasgow Coma Scale (>8) before than after TAE, were positively correlated with survival.

Entities:  

Mesh:

Year:  2007        PMID: 18054013     DOI: 10.1016/j.injury.2007.07.020

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  2 in total

Review 1.  Management of maxillofacial trauma in emergency: An update of challenges and controversies.

Authors:  Anson Jose; Shakil Ahmed Nagori; Bhaskar Agarwal; Ongkila Bhutia; Ajoy Roychoudhury
Journal:  J Emerg Trauma Shock       Date:  2016 Apr-Jun

2.  Endovascular treatment of traumatic oronasal hemorrhage complicated with progressive acute epidural hemorrhage: A case report.

Authors:  Zhinan Ye; Hanghuang Jin; Yuan Chen; Hailong Ji; Hao Xu; Yong Jin
Journal:  Medicine (Baltimore)       Date:  2022-01-21       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.